- Home
- PRQR vs CRDF Comparison
PRQR vs CRDF Comparison
Compare PRQR & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- CRDF
- Stock Information
- Founded
- PRQR 2012
- CRDF 1999
- Country
- PRQR Netherlands
- CRDF United States
- Employees
- PRQR N/A
- CRDF N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRQR Health Care
- CRDF Health Care
- Exchange
- PRQR Nasdaq
- CRDF Nasdaq
- Market Cap
- PRQR 244.4M
- CRDF 233.5M
- IPO Year
- PRQR 2014
- CRDF N/A
- Fundamental
- Price
- PRQR $2.17
- CRDF $2.39
- Analyst Decision
- PRQR Strong Buy
- CRDF Strong Buy
- Analyst Count
- PRQR 8
- CRDF 6
- Target Price
- PRQR $8.88
- CRDF $10.58
- AVG Volume (30 Days)
- PRQR 201.7K
- CRDF 3.2M
- Earning Date
- PRQR 08-07-2025
- CRDF 07-29-2025
- Dividend Yield
- PRQR N/A
- CRDF N/A
- EPS Growth
- PRQR N/A
- CRDF N/A
- EPS
- PRQR N/A
- CRDF N/A
- Revenue
- PRQR $20,129,184.00
- CRDF $545,000.00
- Revenue This Year
- PRQR N/A
- CRDF N/A
- Revenue Next Year
- PRQR N/A
- CRDF N/A
- P/E Ratio
- PRQR N/A
- CRDF N/A
- Revenue Growth
- PRQR 8.65
- CRDF N/A
- 52 Week Low
- PRQR $1.07
- CRDF $2.09
- 52 Week High
- PRQR $4.62
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- PRQR 51.89
- CRDF 32.39
- Support Level
- PRQR $2.16
- CRDF $2.29
- Resistance Level
- PRQR $2.15
- CRDF $2.79
- Average True Range (ATR)
- PRQR 0.14
- CRDF 0.32
- MACD
- PRQR -0.03
- CRDF -0.15
- Stochastic Oscillator
- PRQR 42.11
- CRDF 4.48
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.